This commentary aims to move the debate regarding the adoption of HbA(1c) for diagnosis of type 2 diabetes forwards by highlighting the need to avoid addressing irrelevant questions, in particular, comparison of individuals diagnosed with different diagnostic criteria. Instead, we provide a list of important future questions, including whether adoption of HbA(1c) as the primary diagnostic test improves uptake of diabetes screening, with resultant earlier diagnosis and improvement in outcomes.